"Janus Kinase 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A Janus kinase subtype that is involved in signaling from GROWTH HORMONE RECEPTORS; PROLACTIN RECEPTORS; and a variety of CYTOKINE RECEPTORS such as ERYTHROPOIETIN RECEPTORS and INTERLEUKIN RECEPTORS. Dysregulation of Janus kinase 2 due to GENETIC TRANSLOCATIONS have been associated with a variety of MYELOPROLIFERATIVE DISORDERS.
Descriptor ID |
D053614
|
MeSH Number(s) |
D08.811.913.696.620.682.725.124.200 D12.776.476.393.200 D12.776.624.664.700.117
|
Concept/Terms |
Janus Kinase 2- Janus Kinase 2
- JAK-2 Protein Tyrosine Kinase
- JAK 2 Protein Tyrosine Kinase
- JAK2 Protein Tyrosine Kinase
|
Below are MeSH descriptors whose meaning is more general than "Janus Kinase 2".
Below are MeSH descriptors whose meaning is more specific than "Janus Kinase 2".
This graph shows the total number of publications written about "Janus Kinase 2" by people in this website by year, and whether "Janus Kinase 2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1996 | 0 | 1 | 1 |
1998 | 0 | 1 | 1 |
1999 | 0 | 3 | 3 |
2000 | 0 | 2 | 2 |
2002 | 0 | 1 | 1 |
2003 | 0 | 1 | 1 |
2005 | 0 | 7 | 7 |
2006 | 4 | 10 | 14 |
2007 | 11 | 5 | 16 |
2008 | 7 | 5 | 12 |
2009 | 11 | 5 | 16 |
2010 | 13 | 7 | 20 |
2011 | 14 | 9 | 23 |
2012 | 8 | 9 | 17 |
2013 | 9 | 5 | 14 |
2014 | 9 | 6 | 15 |
2015 | 13 | 9 | 22 |
2016 | 7 | 10 | 17 |
2017 | 11 | 8 | 19 |
2018 | 7 | 7 | 14 |
2019 | 5 | 7 | 12 |
2020 | 4 | 6 | 10 |
2021 | 2 | 6 | 8 |
2022 | 0 | 13 | 13 |
2023 | 1 | 13 | 14 |
2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Janus Kinase 2" by people in Profiles.
-
Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib. Haematologica. 2024 Feb 01; 109(2):676-681.
-
Optical Genome Mapping Helps to Identify BCR::JAK2 Rearrangement Arising from Cryptic Complex Chromosomal Aberrations: A Case Report and Literature Review. Genes (Basel). 2023 Dec 08; 14(12).
-
Moving toward disease modification in polycythemia vera. Blood. 2023 11 30; 142(22):1859-1870.
-
Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis. Blood Adv. 2023 10 10; 7(19):5835-5842.
-
New era for myelofibrosis treatment with novel agents beyond Janus kinase-inhibitor monotherapy: Focus on clinical development of BCL-XL /BCL-2 inhibition with navitoclax. Cancer. 2023 11 15; 129(22):3535-3545.
-
Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety. J Hematol Oncol. 2023 07 27; 16(1):82.
-
Acute myeloid leukemias with JAK2/STAT mutations are associated with PD-L1 upregulation. Leuk Lymphoma. 2023 10; 64(10):1662-1672.
-
Moving beyond ruxolitinib failure in myelofibrosis: evolving strategies for second line therapy. Expert Opin Pharmacother. 2023 Jun; 24(9):1091-1100.
-
A PKM2 inhibitor induces apoptosis and autophagy through JAK2 in human oral squamous cell carcinoma cells. Chem Biol Interact. 2023 Aug 01; 380:110538.
-
Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy. Leuk Lymphoma. 2023 06; 64(6):1063-1081.